10-K: Interpace Biosciences Shifts Focus After PancraGEN Loss

Interpace Biosciences reports a significant net income increase in 2025 driven by a tax benefit, despite an 18% revenue decline following the discontinuation of its PancraGEN test.

Summary

• Net income increased to $24.6 million in 2025 from $6.7 million in 2024, primarily due to a $21.2 million income tax benefit from the partial release of a valuation allowance.
• Consolidated revenue decreased by 18% to $38.7 million in 2025, down from $46.9 million in 2024, mainly driven by the loss of reimbursement for the PancraGEN test.
• The company discontinued its PancraGEN test after the Center for Medicare and Medicaid Services (CMS) ceased reimbursement coverage on April 24, 2025, and stopped accepting specimens after May 2, 2025.
• Current efforts are concentrated on molecular diagnostic tests for thyroid cancer, ThyGeNEXT and ThyraMIRv2.
• Operating income from continuing operations decreased to $4.1 million in 2025 from $8.1 million in 2024.
• Gross profit decreased by 19% to $24.1 million in 2025, compared to $29.9 million in 2024.
• A restructuring plan was implemented in April 2025, resulting in a workforce reduction and $0.7 million in severance and related costs.
• Cash and cash equivalents were $2.5 million as of December 31, 2025, and approximately $2.4 million as of March 20, 2026.
• All Series C Preferred Stock was converted into approximately 23,267,327 shares of common stock on January 20, 2026.
• Ampersand and 1315 Capital, two private equity firms, collectively control 84% of the company's outstanding common stock (50% and 34% respectively).
• The company's common stock was delisted from Nasdaq in February 2021, removed from OTCQX on August 18, 2025, and now trades on the OTCID tier.
• A material weakness in internal control over financial reporting related to the review of complex agreements was remediated by December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for Interpace Biosciences, marked by significant revenue decline and market delisting, partially offset by a one-time tax benefit and strategic focus on thyroid diagnostics. The operational challenges and market position warrant caution.

Positives

• Net income significantly increased to $24.6 million in 2025, primarily driven by a $21.2 million income tax benefit from the partial release of a valuation allowance.
• Generated positive cash flows from operating activities of $5.8 million for the year ended December 31, 2025.
• The BroadOak Term Loan was fully repaid in November 2025, reducing debt obligations.
• Successfully remediated a material weakness in internal control over financial reporting by December 31, 2025.
• The conversion of all Series C Preferred Stock to common stock simplifies the company's capital structure.
• Management anticipates current cash and forecasted cash receipts will be sufficient to meet anticipated cash requirements through the next twelve months from the filing date.

Negatives

• Consolidated revenue decreased by 18% to $38.7 million in 2025 from $46.9 million in 2024.
• The discontinuation of the PancraGEN test due to loss of CMS reimbursement significantly impacted revenue and operating results.
• Operating income from continuing operations decreased by 49.6% to $4.1 million in 2025 from $8.1 million in 2024.
• Gross profit decreased by 19% to $24.1 million in 2025 from $29.9 million in 2024.
• Sales and marketing expenses decreased due to a reduction in salesforce size as part of the restructuring, indicating a contraction in commercial efforts.
• The company's common stock was delisted from Nasdaq in February 2021, removed from OTCQX on August 18, 2025, and now trades on OTCID, which typically has lower liquidity and higher volatility.
• A high concentration of ownership (84%) by two private equity firms may have a substantial influence on company decisions, potentially limiting the influence of other shareholders.
• Cost of revenue as a percentage of revenue increased to approximately 38% in 2025 from 36% in 2024, indicating reduced efficiency.

Risks

• Dependence on a few payers, including CMS, for a significant portion of revenue, with the risk of reimbursement changes or discontinuations, as experienced with the PancraGEN test.
• Reliance on sales and reimbursements from ThyGeNEXT and ThyraMIRv2 for all revenue, requiring sufficient generation from these and future products to grow the business.
• Potential future issuance of preferred stock could reduce the value of common stock.
• The controlling interests of two private equity firms (84% aggregate ownership) may have a substantial influence on company decisions.
• The delisting from Nasdaq and subsequent trading on OTCID has adversely affected and may continue to adversely affect common stock and business, potentially limiting the ability to raise capital.
• Risk of not being able to successfully implement future restructuring activities or other significant organizational changes.
• The loss of members of the senior management team or inability to attract and retain key personnel could adversely affect the business.
• Failure to comply with federal, state, and foreign laboratory licensing requirements could lead to the loss of ability to perform tests or business disruptions.
• Legislation reforming the U.S. healthcare system may have a material adverse effect on financial condition and operations.
• The ability to use net operating loss carryforwards may be limited, potentially resulting in increased future tax liability.
• Acquisitions of businesses or assets or investments in other companies or technologies could harm operating results, dilute stockholder ownership, increase debt, or incur significant expense.
• The price and trading volume of common stock may be highly volatile and could suffer a decline in value.
• Risk of being sued for product liability or errors and omissions liability related to tests and services, potentially leading to substantial liabilities.
• Failure to comply with fraud and abuse laws or payer regulations could result in exclusion from participation in Medicare, Medicaid, or other governmental payer programs, subject to fines, penalties, and repayment obligations.
• A catastrophe striking the laboratory or it becoming inoperable for any other reason would prevent testing and harm the business.
• Liability for damages if hazardous materials are used in a manner that causes contamination or injury.
• Security breaches, loss of data, and other disruptions to the company or its third-party service providers could compromise sensitive information and expose the company to liability.
• Difficulties in managing growth or reductions in the size of the organization.
• Inability to license rights to use third-party technologies on reasonable terms could prevent commercialization of new products or services.
• Unfavorable results of legal proceedings could have a material adverse effect on business, financial condition, and results of operations.
• Failure to protect intellectual property effectively would harm the business.
• Changes in U.S. patent law could diminish the value of patents, impairing the ability to protect molecular diagnostic tests.
• Involvement in litigation related to intellectual property could be time-intensive and costly.
• Comprehensive tax reform could adversely affect business and financial condition.
• Global economic and political instability and geopolitical events could adversely affect business, financial condition, or results of operations.
• Risks associated with penny stock classification could affect the marketability of common stock.
• Increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies.
• Any weakness in disclosure controls and procedures and internal controls could have a material adverse effect.
• Anti-takeover defenses could delay or prevent an acquisition and adversely affect the price of common stock.
• Securities litigation is expensive and could divert management's attention.
• Indemnification rights provided to directors, officers, and employees may result in substantial expenditures and discourage lawsuits against them.

Future Outlook

The company aims to drive exceptional growth and become a leader in providing high-quality and dependable personalized medicine. Its strategy involves expanding awareness and use of existing commercial products, ThyGeNEXT and ThyraMIRv2, through omnichannel marketing programs. Future plans include implementing automation for improved operating efficiencies, broadening insurance coverage and reimbursement, and expanding commercial sales staff. The company will also explore partnering or acquisition opportunities for new technologies and products and diversify its product portfolio through research and development. Management anticipates that current cash and forecasted cash receipts will be sufficient to meet anticipated cash requirements through the next twelve months from the filing date. The company intends to seek an uplisting of its common stock to Nasdaq, though no assurances can be given that a Nasdaq listing will be achieved.

Management Comments

• "We are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT and ThyraMIRv2."
• "Our primary goal is to drive exceptional growth while becoming a leader in providing high-quality and dependable personalized medicine."
• "We expect to continue to further develop our existing endocrine assays and to also expand our presence in other markets where we have expertise and access."
• "We believe that the specialty molecular diagnostics market offers significant growth and strong patient value given the substantial opportunity it affords to lower healthcare costs by helping to reduce unnecessary surgeries."
• "We are keenly focused on growing our test volumes; securing additional insurance coverage and reimbursement; maintaining and growing our current reimbursement; supporting revenue growth for our molecular diagnostic tests; and expanding our business by developing and promoting synergistic products in our markets."
• "The Company anticipates that current cash and cash equivalents and forecasted cash receipts will be sufficient to meet its anticipated cash requirements through the next twelve months from the date of the filing of this report."

Industry Context

StockSavvy.ai notes that Interpace Biosciences operates in the rapidly growing global esoteric molecular diagnostics market, valued at $29.6 billion in 2025 and projected to reach $75.9 billion by 2034, indicating a strong underlying market trend. The company's strategic shift to focus solely on thyroid cancer diagnostics (ThyGeNEXT and ThyraMIRv2) after the loss of PancraGEN reimbursement positions it within a competitive but high-value segment of oncology diagnostics, aiming to reduce unnecessary surgeries and healthcare costs. The broader U.S. clinical oncology market continues to face significant unmet medical needs, with cancer remaining a leading cause of mortality and associated medical care costs projected to rise dramatically, underscoring the importance of advanced diagnostic solutions.

Comparison to Industry Standards

• Interpace Biosciences competes directly with Veracyte, Inc., which offers the molecular thyroid nodule cancer diagnostic test (Afirma), a current market leader.
• Quest Diagnostics Incorporated, a major industry player, offers a diagnostic test similar to an earlier version of ThyGeNEXT and distributes the Afirma test in partnership with Veracyte.
• Sonic Healthcare USA, Inc. offers ThyroSeq, another diagnostic test that analyzes genetic alterations using next-generation sequencing, providing direct competition in the thyroid diagnostic space.
• The company's combined ThyGeNEXT and ThyraMIRv2 testing platform aims to provide high-performance metrics and narrow malignancy risk ranges, positioning it against established and widely adopted tests like Afirma.
• The estimated total market for endocrine (thyroid) cancer assays is approximately $300 million annually, indicating a significant but highly competitive niche where Interpace Biosciences must differentiate its offerings and secure reimbursement against larger, more established competitors.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May from time to time become involved in legal proceedings arising in the ordinary course of business.

Related Party Transactions

• On October 10, 2024, the company entered into an Exchange Agreement with Ampersand 2018 Limited Partnership and 1315 Capital II, L.P. (the Investors) to exchange all 47,000 shares of Series B convertible preferred stock for 47,000 newly created shares of Series C Preferred Stock.
• On January 13, 2026, Ampersand converted its 28,000 shares of Series C Preferred Stock into 13,861,386 shares of common stock.
• On January 15, 2026, 1315 Capital converted its 19,000 shares of Series C Preferred Stock into 9,405,941 shares of common stock.
• Ampersand and 1315 Capital collectively control 84% of the company's outstanding common stock as of February 28, 2026.
• The Term Loan with BroadOak Fund V, L.P. (a significant lender) was paid in full in November 2025.

Stakeholder Impact

• Shareholders face dilution risk from potential future equity offerings, increased volatility and reduced liquidity due to trading on OTCID, and limited influence due to significant ownership concentration by private equity firms.
• Employees experienced workforce reductions as part of the restructuring plan, though severance benefits were provided; the company's success depends on attracting and retaining highly skilled personnel in a competitive market.
• Customers (physicians, hospitals, clinics) will see a continued focus on thyroid cancer diagnostics (ThyGeNEXT and ThyraMIRv2) and potential new diagnostic solutions, but may be impacted by changes in reimbursement policies and coverage.
• Payers (Medicare, commercial insurers) are central to the company's revenue, with ongoing efforts to secure and maintain coverage and reimbursement rates for its tests, and potential for increased scrutiny on billing practices.
• Suppliers face risks related to the company's reliance on sole-source providers for certain materials, which could lead to supply chain disruptions if alternative sources are not available or quality specifications are not met.

Next Steps

• Expand awareness and use of existing commercial products, ThyGeNEXT and ThyraMIRv2, through omnichannel marketing programs.
• Implement automation and focus on improved operating efficiencies in the clinical laboratories to provide consistent superior quality testing and reporting at reduced costs.
• Broaden coverage and reimbursement for clinical tests by continuing support of an internal managed care team, utilizing Key Opinion Leaders, and establishing payer relationships and in-network contracts.
• Expand commercial sales staff rationally, while supporting products with high-quality data and studies.
• Explore partnering or other opportunities to acquire new technologies and products.
• Expand understanding and utilization of bioinformatics data to improve assays and elevate scientific understanding of the genetic drivers of cancer progression and aggressiveness.
• Diversify the product portfolio and explore new revenue streams, including investing in research and development to bring innovative diagnostic solutions to market.
• Strengthen relationships with commercial payers to ensure broader coverage for tests.
• Seek an uplisting of its common stock to Nasdaq.

Key Dates

Recommendation

The company experienced a significant 18% revenue decline and a nearly 50% drop in operating income in 2025, primarily due to the discontinuation of its PancraGEN test. While net income was boosted by a one-time tax benefit, this does not reflect sustainable operational improvement. The stock's delisting from Nasdaq and subsequent trading on the less liquid OTCID, coupled with significant ownership concentration by private equity firms, presents substantial risks to liquidity and investor influence. The ongoing challenges in securing and maintaining reimbursement for its remaining tests, along with intense competition, suggest a difficult path to consistent profitability and growth, making it a 'sell' for seasoned investors.

Keywords

molecular diagnostics, thyroid cancer, ThyGeNEXT, ThyraMIRv2, SEC filing, 10-K, financial results, healthcare, biotechnology, genomic testing, CMS reimbursement, PancraGEN, OTC Markets, corporate governance, risk factors, financial reporting, clinical laboratory, CLIA, CAP, private equity, stock volatility, restructuring